Oncternal Therapeutics, Inc.: Nasdaq/NYSE listing notice — Oncternal gets 180-day Nasdaq extension to April 1, 2024 to regain bid price compliance

Oncternal Therapeutics, Inc.

Nasdaq granted an additional 180 days, to April 1, 2024, to meet the $1.00 minimum bid price rule.
Original non-compliance notice issued April 4, 2023 after bid closed below $1.00 for 30 consecutive days.
Stockholders approved a reverse stock split (1:5 to 1:30) at June 28, 2023 annual meeting to cure deficiency.
If not compliant by April 1, 2024, Nasdaq will issue delisting notice; company may appeal.
No assurance compliance will be regained or that other listing requirements will be maintained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Oncternal Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 3, 2023, Nasdaq notified Oncternal that it has granted Oncternal an additional 180 calendar days, or to April 1, 2024, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). Oncternal intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, Oncternal has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock, to attempt to regain compliance. At Onct

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-052419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.